Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938475 | 0.83 | LDHA (0.33) | FFAR3LDHASRR | |
| SCHEMBL452971 | 0.78 | ALDH1A1 (0.34) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2957096 | 0.76 | FFAR3 (0.31) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5862450 | 0.74 | LMNA (0.32) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7642543 | 0.74 | LDHA (0.36) | LDHASRR | |
| Butane SCHEMBL14890902 | 0.72 | MEN1 (0.39) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2710907 | 0.72 | LDHA (0.38) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL26978678 | 0.71 | PAM (0.39) | — | |
| SCHEMBL22092195 | 0.71 | AKR1B1 (0.40) | — | |
| SCHEMBL2967817 | 0.70 | LDHA (0.36) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | FFAR3 417/4885HDAC3 218/4885HDAC1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.